Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

11.590
+0.6005.46%
Volume:6.63M
Turnover:76.23M
Market Cap:29.76B
PE:18.41
High:11.650
Open:11.520
Low:11.150
Close:10.990
52wk High:14.247
52wk Low:9.070
Shares:2.57B
HK Float Shares:2.57B
Volume Ratio:5.65
T/O Rate:0.26%
Dividend:0.21
Dividend Rate:1.81%
EPS(LYR):0.630
ROE:18.77%
ROA:7.78%
PB:2.71
PE(LYR):18.41
PS:2.92

Loading ...

Simcere Pharma Issues AGM Notice, Proposes RMB0.18 Final Dividend and Director Re-election

Bulletin Express
·
May 21

Simcere Pharma reports 26.67 million-share buyback awaiting cancellation; issued share count unchanged

Bulletin Express
·
May 21

SIMCERE PHARMA Executes HK$21.74 Million Share Buyback

Stock News
·
May 20

Simcere Pharma further buys back 2.58 million shares; YTD repurchases reach 20.57 million

Bulletin Express
·
May 19

Simcere files HKEX next-day return, discloses share buyback at HKD 11.48 each

Reuters
·
May 19

Simcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million

Bulletin Express
·
May 19

SIMCERE PHARMA Spends HK$17.99 Million on Share Buyback

Stock News
·
May 19

SIMCERE PHARMA Executes Share Repurchase on May 18

Stock News
·
May 18

Simcere files HKEX return disclosing share repurchase at HKD 11.19 each

Reuters
·
May 18

SIMCERE PHARMA Executes Share Buyback on May 14

Stock News
·
May 15

SIMCERE PHARMA (02096) Spends HK$12.30 Million on Share Buyback

Stock News
·
May 13

Simcere files HKEX next-day return, discloses share repurchase at HKD 11.57 each

Reuters
·
May 13

Simcere Pharmaceutical Group's (HKG:2096) Solid Profits Have Weak Fundamentals

Simply Wall St.
·
May 08

Simcere Pharma Keeps Share Capital Unchanged in April 2026, Public Float Remains Compliant

Bulletin Express
·
May 06

Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug

MT Newswires Live
·
May 06

BRIEF-Simcere Pharmaceutical Receives NMPA China Clinical Trial Approval For SIM0613

Reuters
·
May 06

Simcere Pharma receives NMPA approval to begin clinical trial of LRRC15 ADC SIM0613; partnership with Ipsen worth up to US$1.06 billion progresses

Bulletin Express
·
May 06

SIMCERE PHARMA's ADC Candidate SIM0613 Receives Chinese Regulatory Nod for Clinical Trials

Stock News
·
May 06

Simcere Pharmaceutical - Receives China Clinical Trial Approval From Nmpa for Sim0613 in Advanced Solid Tumors

THOMSON REUTERS
·
May 06

Simcere Pharma buys back 1.38 million shares on 5 May; cumulative 2026 repurchases reach 15.05 million

Bulletin Express
·
May 05